Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
Status:
Recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II, single-arm, multi-center study of neoadjuvant osimertinib in combination
with chemotherapy for the treatment of patients with resectable EGFR-mutant stage III (N2)
non-squamous non-small cell lung cancer